| Report ID | 277602 |
| Drug Identification Number | 02408880 |
| Brand name | MINT-GABAPENTIN |
| Common or Proper name | Gabapentin |
| Company Name | MINT PHARMACEUTICALS INC |
| Market Status | MARKETED |
| Active Ingredient(s) | GABAPENTIN |
| Strength(s) | 100MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | 500 count bottle |
| Anatomical Therapeutical Chemical (ATC) code | N02BF |
| Anatomical Therapeutical Chemical (ATC) description | |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2026-02-06 |
| Estimated end date | |
| Actual end date | 2026-05-30 |
| Shortage status | Actual shortage |
| Updated date | 2026-02-09 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 6575 DAVAND DRIVE MISSISSAUGA, ONTARIO CANADA L5T 2M3 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-02-09 | French | Compare |
| v1 | 2026-02-09 | English | Compare |
Showing 1 to 2 of 2